AR071345A1 - Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del sindrome metabolico - Google Patents
Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del sindrome metabolicoInfo
- Publication number
- AR071345A1 AR071345A1 ARP090100397A ARP090100397A AR071345A1 AR 071345 A1 AR071345 A1 AR 071345A1 AR P090100397 A ARP090100397 A AR P090100397A AR P090100397 A ARP090100397 A AR P090100397A AR 071345 A1 AR071345 A1 AR 071345A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- alkyl
- substituted
- treatment
- alkylene
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
El uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabolico La solicitud se refiere al uso de los compuestos de la formula 1 en el que los radicales son cada uno definidos como se especifica para producir un medicamento para el tratamiento del síndrome metabolico. Reivindicacion 1: El uso de los compuestos de formula 1, en la que R1 es -CN, -NO2, halogeno; R2 es -CF3, halogeno; -A-B- se selecciona del grupo que consiste en formula (2) y formula (3), X es O o S; R3 es hidrogeno, alquilo C1-12, alquenilo C1-12 y alquinilo C2-12, arilo C6- 12, alquilen C1-12-arilo C6-12, donde, en alquilo C1-2, alquenilo C2-12, alquinilo C2-1 y alquilen C1-12-arilo C6-12, al menos un carbono puede ser opcionalmente sustituido por un átomo del grupo de oxigeno, nitrogeno y azufre, donde el azufre puede haber sido opcionalmente oxidado a sulfoxido o sulfona; donde arilo C6-12 y alquilen C1-12-arilo C6-12 puede ser sustituido por un sustituyente del grupo de halogeno, -CF3, alquilo C1-6, alcoxi C1-6, alquenilo C2-6, alqueniloxi C2-6, alquinilo C2-6 y alquiniloxi C2-6; y donde alquilo C1-12, alquenilo C2-12, alquinilo C2-12, arilo C6-12 y alquilen C1-12-arilo C6-12 pueden ser sustituidos por -OH, halogeno, -SH, -CN, COO-alquilo C1-12, [-O(C=O)-arilo C6-12)], COOH, carboxilato (COO-), alquilen C1-12-COOH, -NH2, NH-alquilo C1-12, N-[alquil (C1-12)]2, CONH2, -(C=O)-NH-alquilo C1-12, -(C=O)-N-[alquil (C1-12)]]2, acilo, aciloxi C1-7, arilo C6-12, -O-arilo C6-12, -O-alquilen C1-12-arilo C6-12, -S-arilo C6-12, -S(O)-arilo C6-12, -SO2-arilo C6-12, trialquilsililo C1-12, donde el alquilo tiene de 1 a 6 átomos de carbono; Y es O, S, NH; y de sus sales fisiologicamente compatibles para producir un medicamento para el tratamiento del síndrome metabolico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290132 | 2008-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071345A1 true AR071345A1 (es) | 2010-06-16 |
Family
ID=39502138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100397A AR071345A1 (es) | 2008-02-07 | 2009-02-05 | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del sindrome metabolico |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR071345A1 (es) |
| CL (1) | CL2009000257A1 (es) |
| TW (1) | TW200946114A (es) |
| UY (1) | UY31646A1 (es) |
| WO (1) | WO2009097996A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011140190A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Tetrazolones as inhibitors of fatty acid synthase |
| WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| BR112019014529A2 (pt) * | 2017-01-18 | 2020-02-27 | Coherus Biosciences, Inc. | Agonista de ppargama para tratamento de doença de huntington |
| EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
| CN112759550A (zh) * | 2019-11-04 | 2021-05-07 | 上海科技大学 | 一种平滑受体拮抗剂 |
| CN113024513A (zh) * | 2021-03-22 | 2021-06-25 | 中国药科大学 | 新型雄激素受体降解剂、制备方法和医药用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2693461B1 (fr) * | 1992-07-08 | 1994-09-02 | Roussel Uclaf | Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
-
2009
- 2009-01-30 WO PCT/EP2009/000589 patent/WO2009097996A1/de active Application Filing
- 2009-02-05 CL CL2009000257A patent/CL2009000257A1/es unknown
- 2009-02-05 AR ARP090100397A patent/AR071345A1/es unknown
- 2009-02-05 TW TW098103592A patent/TW200946114A/zh unknown
- 2009-02-06 UY UY031646A patent/UY31646A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200946114A (en) | 2009-11-16 |
| UY31646A1 (es) | 2009-08-31 |
| CL2009000257A1 (es) | 2009-06-26 |
| WO2009097996A1 (de) | 2009-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071345A1 (es) | Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del sindrome metabolico | |
| PE20110906A1 (es) | Compuestos de arilo con sustituyentes heterociclicos como inhibidores hif | |
| AR080328A1 (es) | Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros | |
| PE20091623A1 (es) | DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA | |
| AR052156A1 (es) | Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20091444A1 (es) | Derivados de isoxazolo-pirazina | |
| PE20061303A1 (es) | Composicion farmaceutica que comprende oxaprozina | |
| HRP20120963T1 (hr) | PIRIDO-, PIRAZO- I PIRIMIDOPIRIMIDINSKI DERIVATI KAO mTOR INHIBITORI | |
| ATE534377T1 (de) | Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen | |
| AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| BRPI0607728A2 (pt) | complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado | |
| PE20091561A1 (es) | Compuestos inhibidores de raf y metodos para su uso | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| PE20081493A1 (es) | Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso | |
| RU2008142834A (ru) | Модуляция церамидкиназы | |
| CO6612267A2 (es) | Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden | |
| AR065813A1 (es) | Compuesto composicion farmaceutica y metodos para tratar trastornos relacionados con pi3k y mtor y a cancer y para inhibir mtor y pi3k | |
| PE20081800A1 (es) | NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA | |
| SV2008002958A (es) | Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania referencia cruzada ref. prd2592sv | |
| PE20090655A1 (es) | Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |